Which has preferable earnings & valuation, DRIO or RXST?

RxSight has higher revenue and earnings than DarioHealth. RxSight is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DarioHealth $22.36M 1.96 -$41.71M -$8.88 N/A RxSight $127.48M 1.70 -$38.94M -$1.13 N/A

Is DRIO or RXST more profitable?

RxSight has a net margin of -36.58% compared to DarioHealth's net margin of -192.23%. RxSight's return on equity of -17.01% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets DarioHealth -192.23% -60.52% -37.08% RxSight -36.58% -17.01% -15.12%

Which has higher valuation & earnings, PDEX or DRIO?

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.04 $8.98M $3.62 17.51 DarioHealth $22.36M 1.96 -$41.71M -$8.88 N/A

Is PDEX or DRIO more profitable?

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% DarioHealth -192.23% -60.52% -37.08%

Which has stronger valuation & earnings, DRIO or EMBC?

Embecta has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DarioHealth $22.36M 1.96 -$41.71M -$8.88 N/A Embecta $1.08B 0.17 $95.40M $1.90 1.65

Is DRIO or EMBC more profitable?

Embecta has a net margin of 10.73% compared to DarioHealth's net margin of -192.23%. Embecta's return on equity of -23.96% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets DarioHealth -192.23% -60.52% -37.08% Embecta 10.73% -23.96% 14.12%

DarioHealth (DRIO) Competitors

$5.99 -0.35 (-5.52%)

Closing price 06/23/2026 03:59 PM Eastern

Extended Trading

$6.51 +0.52 (+8.65%)

As of 08:38 AM Eastern

Compare

DRIO vs. LUCD, RXST, PDEX, EMBC, and STEX

Should you buy DarioHealth stock or one of its competitors? MarketBeat compares DarioHealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DarioHealth include Lucid Diagnostics (LUCD), RxSight (RXST), Pro-Dex (PDEX), Embecta (EMBC), and Biosig Technologies (STEX). These companies are all part of the "medical equipment" industry.

How does DarioHealth compare to Lucid Diagnostics?

DarioHealth (NASDAQ:DRIO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, DarioHealth's average media sentiment score of 1.00 beat Lucid Diagnostics' score of 0.00 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Positive
Lucid Diagnostics	Neutral

DarioHealth presently has a consensus target price of $10.50, suggesting a potential upside of 75.29%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 306.55%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DarioHealth has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	1.96	-$41.71M	-$8.88	N/A
Lucid Diagnostics	$5.13M	40.74	-$58.01M	-$0.47	N/A

DarioHealth has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

DarioHealth has a net margin of -192.23% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Summary

Lucid Diagnostics beats DarioHealth on 8 of the 15 factors compared between the two stocks.

How does DarioHealth compare to RxSight?

DarioHealth (NASDAQ:DRIO) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

RxSight has higher revenue and earnings than DarioHealth. RxSight is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	1.96	-$41.71M	-$8.88	N/A
RxSight	$127.48M	1.70	-$38.94M	-$1.13	N/A

DarioHealth currently has a consensus price target of $10.50, suggesting a potential upside of 75.29%. RxSight has a consensus price target of $9.44, suggesting a potential upside of 80.93%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

RxSight has a net margin of -36.58% compared to DarioHealth's net margin of -192.23%. RxSight's return on equity of -17.01% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
RxSight	-36.58%	-17.01%	-15.12%

In the previous week, RxSight had 1 more articles in the media than DarioHealth. MarketBeat recorded 1 mentions for RxSight and 0 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.00 beat RxSight's score of 0.00 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Positive
RxSight	Neutral

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

DarioHealth has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, RxSight has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

RxSight beats DarioHealth on 12 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Pro-Dex has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.04	$8.98M	$3.62	17.51
DarioHealth	$22.36M	1.96	-$41.71M	-$8.88	N/A

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
DarioHealth	-192.23%	-60.52%	-37.08%

Pro-Dex presently has a consensus price target of $70.00, suggesting a potential upside of 10.43%. DarioHealth has a consensus price target of $10.50, suggesting a potential upside of 75.29%. Given DarioHealth's higher possible upside, analysts plainly believe DarioHealth is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Pro-Dex had 2 more articles in the media than DarioHealth. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.00 beat Pro-Dex's score of 0.00 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Pro-Dex	Neutral
DarioHealth	Positive

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 45.9% of Pro-Dex shares are held by company insiders. Comparatively, 3.5% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pro-Dex beats DarioHealth on 11 of the 15 factors compared between the two stocks.

How does DarioHealth compare to Embecta?

DarioHealth (NASDAQ:DRIO) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

In the previous week, Embecta had 29 more articles in the media than DarioHealth. MarketBeat recorded 29 mentions for Embecta and 0 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.00 beat Embecta's score of -0.15 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Positive
Embecta	Neutral

DarioHealth currently has a consensus price target of $10.50, suggesting a potential upside of 75.29%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 251.44%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

Embecta has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	1.96	-$41.71M	-$8.88	N/A
Embecta	$1.08B	0.17	$95.40M	$1.90	1.65

DarioHealth has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Embecta has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 3.5% of DarioHealth shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Embecta has a net margin of 10.73% compared to DarioHealth's net margin of -192.23%. Embecta's return on equity of -23.96% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Embecta	10.73%	-23.96%	14.12%

Summary

Embecta beats DarioHealth on 10 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

DarioHealth has higher revenue and earnings than Biosig Technologies. DarioHealth is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,905.52	-$462.77M	-$9.71	N/A
DarioHealth	$22.36M	1.96	-$41.71M	-$8.88	N/A

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 3.5% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biosig Technologies has a net margin of 0.00% compared to DarioHealth's net margin of -192.23%. DarioHealth's return on equity of -60.52% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
DarioHealth	-192.23%	-60.52%	-37.08%

Biosig Technologies presently has a consensus price target of $8.00, indicating a potential upside of 830.99%. DarioHealth has a consensus price target of $10.50, indicating a potential upside of 75.29%. Given Biosig Technologies' higher probable upside, equities analysts clearly believe Biosig Technologies is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biosig Technologies had 2 more articles in the media than DarioHealth. MarketBeat recorded 2 mentions for Biosig Technologies and 0 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.00 beat Biosig Technologies' score of 0.63 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Positive
DarioHealth	Positive

Biosig Technologies has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

Biosig Technologies and DarioHealth tied by winning 7 of the 14 factors compared between the two stocks.

Get DarioHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRIO vs. The Competition

Export

Metric	DarioHealth	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$46.36M	$7.05B	$6.44B	$12.30B
Dividend Yield	N/A	1.27%	2.69%	5.83%
P/E Ratio	-0.67	48.65	24.66	23.99
Price / Sales	1.96	88.31	531.91	108.06
Price / Cash	N/A	24.78	44.82	54.51
Price / Book	0.60	7.13	10.81	6.50
Net Income	-$41.71M	$159.20M	$3.56B	$336.88M
7 Day Performance	-15.99%	-1.92%	0.93%	-0.16%
1 Month Performance	-23.79%	-2.88%	0.35%	0.76%
1 Year Performance	-58.29%	4.79%	29.69%	28.49%

DarioHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRIO DarioHealth	2.6696 of 5 stars	$5.99 -5.5%	$10.50 +75.3%	-56.3%	$46.36M	$22.36M	N/A	200	Positive News
LUCD Lucid Diagnostics	4.0444 of 5 stars	$1.01 -1.5%	$4.19 +316.7%	-13.4%	$204.09M	$4.71M	N/A	70
RXST RxSight	2.5237 of 5 stars	$4.79 +2.2%	$9.44 +97.4%	-61.4%	$198.10M	$134.48M	N/A	220	News Coverage Positive News
PDEX Pro-Dex	2.1189 of 5 stars	$61.55 -1.2%	$70.00 +13.7%	+51.6%	$196.02M	$66.59M	16.97	140
EMBC Embecta	4.0295 of 5 stars	$3.20 +3.4%	$11.00 +244.3%	-68.1%	$189.56M	$1.08B	1.68	1,850	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRIO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DarioHealth (DRIO) Competitors

DRIO vs. LUCD, RXST, PDEX, EMBC, and STEX

How does DarioHealth compare to Lucid Diagnostics?

Summary

How does DarioHealth compare to RxSight?

Summary

How does DarioHealth compare to Pro-Dex?

Summary

How does DarioHealth compare to Embecta?

Summary

How does DarioHealth compare to Biosig Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DarioHealth (DRIO) Competitors

DRIO vs. LUCD, RXST, PDEX, EMBC, and STEX

How does DarioHealth compare to Lucid Diagnostics?

Does the media prefer DRIO or LUCD?

Do analysts prefer DRIO or LUCD?

Do institutionals and insiders hold more shares of DRIO or LUCD?

Which has higher valuation and earnings, DRIO or LUCD?

Which has more volatility & risk, DRIO or LUCD?

Is DRIO or LUCD more profitable?

Summary

How does DarioHealth compare to RxSight?

Which has preferable earnings & valuation, DRIO or RXST?

Do analysts rate DRIO or RXST?

Is DRIO or RXST more profitable?

Does the media favor DRIO or RXST?

Do insiders and institutionals hold more shares of DRIO or RXST?

Which has more volatility and risk, DRIO or RXST?

Summary

How does DarioHealth compare to Pro-Dex?

Which has more volatility and risk, PDEX or DRIO?

Which has higher valuation & earnings, PDEX or DRIO?

Is PDEX or DRIO more profitable?

Do analysts recommend PDEX or DRIO?

Does the media refer more to PDEX or DRIO?

Do institutionals and insiders believe in PDEX or DRIO?

Summary

How does DarioHealth compare to Embecta?

Does the media favor DRIO or EMBC?

Do analysts rate DRIO or EMBC?

Which has stronger valuation & earnings, DRIO or EMBC?

Which has more risk & volatility, DRIO or EMBC?

Do institutionals and insiders hold more shares of DRIO or EMBC?

Is DRIO or EMBC more profitable?

Summary

How does DarioHealth compare to Biosig Technologies?

Which has better earnings & valuation, STEX or DRIO?

Do institutionals & insiders have more ownership in STEX or DRIO?

Is STEX or DRIO more profitable?

Do analysts rate STEX or DRIO?

Does the media refer more to STEX or DRIO?

Which has more risk and volatility, STEX or DRIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools